NGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the US, the UK & Canada only
New pooled safety data from the RE-COVERTM and RE-COVERTM II phase III trials in acute deep vein thrombosis (DVT) and pulmonary embolism (PE) consistently favour treatment with Pradaxa® 150mg bid over treatment with warfarin. The data are published online today in Circulation.1
Help employers find you! Check out all the jobs and post your resume.
